Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-02-2017 | Retinal Disorders

Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)

Authors: Tina Rike Herold, Kristina Rist, Siegfried Georg Priglinger, Michael Werner Ulbig, Armin Wolf

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2017

Abstract

Purpose

To evaluate the long-term results of spironolactone in non-resolving central serous chorio-retinopathy (CSCR) and recurrence rates of CSCR.

Methods

Interventional uncontrolled open-label prospective clinical trial of patients with non-resolving CSCR who were treated with spironolactone 50 mg daily (Spironolacton AL® 50 mg, ALIUD PHARMA) for up to 16 weeks. Follow-up visits were performed at 3, 6, 9, and 12 months. Retreatment criteria for recurrence were: gain in sub-retinal fluid (SRF) of more than 25 % plus/or increase of central retinal thickness (CRT) of more than 50 μm plus visual symptoms compared to last visit. Main outcome measures: 12-month efficacy of upload treatment with spironolactone. Secondary outcome measure was the recurrence rate at 6, 9, and 12 months.

Results

Of the 21 study eyes treated, 71 % (n = 15) showed significant improvement or complete regression on OCT examination over 12 months. Nineteen percent of the patients (n = 4) showed a stable course from visit 1 to visit 12. The overall reduction of sub-retinal fluid from visit 1 (156 μm ± 131 SD) to visit 12 (53 μm ± 93 SD) was statistically significant (p = 0.003). The change of mean visual acuity (log MAR) from 0.25 (± 0.17 SD) at baseline to 0.17 (± 0.18 SD) at visit 12 was statistically significant, with p = 0.044.

Conclusion

Our results confirm a positive effect of spironolactone in non-resolving CSCR in 71 % of cases. Evaluation of recurrence rates and retreatments showed good results in patients who responded to spironolactone primarily.

A prospective randomized trial may provide better data about this non-invasive treatment.

Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68(11):815–820. doi:10.1136/bjo.68.11.815 CrossRefPubMedPubMedCentral

Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115(1):169–173. doi:10.1016/j.ophtha.2007.02.032 CrossRefPubMed

Steinle NC, Gupta N, Yuan A, Singh RP (2012) Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy. Br J Ophthalmol 96(1):10–13. doi:10.1136/bjophthalmol-2011-300183 CrossRefPubMed

Roisman L, Magalhaes FP, Lavinsky D, Moraes N, Hirai FE, Cardillo JA, Farah ME (2013) Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina 44(5):465–470. doi:10.3928/23258160-20130909-08 CrossRefPubMed

Beger I, Koss MJ, Koch F (2012) Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab. Ophthalmologe 109(12):1224–1232. doi:10.1007/s00347-012-2688-7 CrossRefPubMed

Behnia M, Khabazkhoob M, Aliakbari S, Abadi AE, Hashemi H, Pourvahidi P (2013) Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy. Retina 33(2):324–328. doi:10.1097/IAE.0b013e3182670fa3 CrossRefPubMed

Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF (2014) Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121(5):1073–1078. doi:10.1016/j.ophtha.2013.11.040 CrossRefPubMed

Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29(10):1469–1473. doi:10.1097/IAE.0b013e3181be0a83 CrossRefPubMed

Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16(3):203–213CrossRefPubMed

10.

Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122(7):2672–2679. doi:10.1172/jci61427 CrossRefPubMedPubMedCentral

11.

Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33(10):2096–2102. doi:10.1097/IAE.0b013e318297a07a CrossRefPubMed

12.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341(10):709–717. doi:10.1056/nejm199909023411001 CrossRefPubMed

13.

Delyani JA (2000) Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 57(4):1408–1411. doi:10.1046/j.1523-1755.2000.00983.x CrossRefPubMed

14.

Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW (2014) Spironolactone in the treatment of central serous chorioretinopathy - a case series. Graefes Arch Clin Exp Ophthalmol 252(12):1985–1991. doi:10.1007/s00417-014-2780-6 CrossRefPubMed

15.

Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP (2014) Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 111(2):173–180. doi:10.1007/s00347-013-3001-0 CrossRefPubMed

16.

Bousquet E, Beydoun T, Rothschild PR, Bergin C, Zhao M, Batista R, Brandely ML, Couraud B, Farman N, Gaudric A, Chast F, Behar-Cohen F (2015) Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina 35(12):2505–2515. doi:10.1097/IAE.0000000000000614 CrossRefPubMedPubMedCentral

17.

Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41(2):201–214. doi:10.1111/j.1442-9071.2012.02848.x CrossRefPubMed

18.

Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, Behar-Cohen F (2016) Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vision Sci Technol 5(2):2. doi:10.1167/tvst.5.2.2 CrossRef

19.

Kapoor KG, Wagner AL (2016) Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis. Ophthalmic Res 56(1):17-22. doi:10.1159/000444058 CrossRefPubMed

20.

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. doi:10.1016/j.preteyeres.2015.05.003 CrossRefPubMed

21.

Liegl R, Ulbig MW (2014) Central serous chorioretinopathy. Ophthalmol J Int 232(2):65–76. doi:10.1159/000360014

Title: Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)
Authors: Tina Rike Herold
Kristina Rist
Siegfried Georg Priglinger
Michael Werner Ulbig
Armin Wolf
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3436-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Ophthalmology, 4th Edition, (in print and online) Yanoff M, Duker JS. (2013) ISBN 978-1455-7398-44, Elsevier

The effect of vitreous on proliferative diabetic retinopathy and the response to panretinal photocoagulation

Digital fabrication of orbital prosthesis mold using 3D photography and computer-aided design

Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab

Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors

The clinical depth of field achievable with trifocal and monofocal intraocular lenses: theoretical considerations and proof of concept clinical results